ENTO Annual SG&A
$10.74 M
-$1.25 M-10.42%
31 December 2023
Summary:
As of January 23, 2025, ENTO annual selling, general & administrative expenses is $10.74 million, with the most recent change of -$1.25 million (-10.42%) on December 31, 2023. During the last 3 years, it has risen by +$3.44 million (+47.20%). ENTO annual SG&A is now -41.59% below its all-time high of $18.38 million, reached on December 1, 2021.ENTO Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENTO Quarterly SG&A
$1.69 M
-$1.52 M-47.43%
01 September 2024
Summary:
As of January 23, 2025, ENTO quarterly selling, general & administrative expenses is $1.69 million, with the most recent change of -$1.52 million (-47.43%) on September 1, 2024. Over the past year, it has dropped by -$1.10 million (-39.50%). ENTO quarterly SG&A is now -80.54% below its all-time high of $8.66 million, reached on March 31, 2024.ENTO Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENTO TTM SG&A
-$740.81 M
-$9.92 M-1.36%
01 September 2024
Summary:
As of January 23, 2025, ENTO TTM selling, general & administrative expenses is -$740.81 million, with the most recent change of -$9.92 million (-1.36%) on September 1, 2024. Over the past year, it has dropped by -$751.55 million (-6999.26%). ENTO TTM SG&A is now -8830.35% below its all-time high of $18.38 million, reached on December 1, 2021.ENTO TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENTO Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -10.4% | -39.5% | -6999.3% |
| 3 y3 years | +47.2% | -37.6% | -7305.0% |
| 5 y5 years | +44.1% | -9.4% | -10000.0% |
ENTO Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -41.6% | at low | -80.5% | at low | -44.7% | at low |
| 5 y | 5-year | -41.6% | +77.1% | -80.5% | +351.8% | -217.3% | at low |
| alltime | all time | -41.6% | +222.4% | -80.5% | +351.8% | -8830.4% | at low |
Entero Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.69 M(-47.4%) | $16.34 M(-4.3%) |
| June 2024 | - | $3.21 M(-63.0%) | $17.07 M(+2.3%) |
| Mar 2024 | - | $8.66 M(+210.8%) | $16.70 M(+55.5%) |
| Dec 2023 | $10.74 M(-10.4%) | $2.79 M(+15.0%) | $10.74 M(+6.0%) |
| Sept 2023 | - | $2.42 M(-14.4%) | $10.13 M(-4.5%) |
| June 2023 | - | $2.83 M(+4.7%) | $10.61 M(+3.2%) |
| Mar 2023 | - | $2.70 M(+24.0%) | $10.28 M(-14.2%) |
| Dec 2022 | $11.99 M(-34.8%) | - | - |
| Dec 2022 | - | $2.18 M(-25.0%) | $11.99 M(-6.7%) |
| Sept 2022 | - | $2.90 M(+16.2%) | $12.85 M(-19.5%) |
| June 2022 | - | $2.50 M(-43.3%) | $15.96 M(-6.6%) |
| Mar 2022 | - | $4.41 M(+45.1%) | $17.09 M(-7.0%) |
| Dec 2021 | $18.38 M(+152.0%) | $3.04 M(-49.6%) | $18.38 M(+1.9%) |
| Sept 2021 | - | $6.02 M(+65.9%) | $18.05 M(+29.4%) |
| June 2021 | - | $3.63 M(-36.3%) | $13.94 M(+20.0%) |
| Mar 2021 | - | $5.70 M(+111.1%) | $11.62 M(+59.2%) |
| Dec 2020 | $7.29 M(+20.3%) | $2.70 M(+40.8%) | $7.30 M(+46.8%) |
| Sept 2020 | - | $1.92 M(+46.9%) | $4.97 M(+1.1%) |
| June 2020 | - | $1.30 M(-5.4%) | $4.92 M(-13.3%) |
| Mar 2020 | - | $1.38 M(+269.8%) | $5.67 M(-3.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | $6.06 M(-18.6%) | $373.10 K(-79.9%) | $5.88 M(-22.2%) |
| Sept 2019 | - | $1.86 M(-9.5%) | $7.56 M(+7.7%) |
| June 2019 | - | $2.06 M(+29.0%) | $7.02 M(-1.6%) |
| Mar 2019 | - | $1.59 M(-22.2%) | $7.13 M(-4.3%) |
| Dec 2018 | $7.45 M(-3.1%) | $2.05 M(+55.6%) | $7.45 M(-0.9%) |
| Sept 2018 | - | $1.32 M(-39.2%) | $7.52 M(-8.4%) |
| June 2018 | - | $2.17 M(+13.1%) | $8.21 M(+10.6%) |
| Mar 2018 | - | $1.92 M(-9.6%) | $7.43 M(-3.4%) |
| Dec 2017 | $7.69 M(+86.1%) | $2.12 M(+5.5%) | $7.69 M(+1.1%) |
| Sept 2017 | - | $2.01 M(+45.5%) | $7.60 M(+23.9%) |
| June 2017 | - | $1.38 M(-36.5%) | $6.14 M(+8.8%) |
| Mar 2017 | - | $2.17 M(+6.6%) | $5.64 M(+36.6%) |
| Dec 2016 | $4.13 M(+24.0%) | $2.04 M(+275.1%) | $4.13 M(+47.7%) |
| Sept 2016 | - | $543.70 K(-38.5%) | $2.79 M(-15.2%) |
| June 2016 | - | $884.30 K(+33.7%) | $3.30 M(+2.1%) |
| Mar 2016 | - | $661.60 K(-6.2%) | $3.23 M(-3.1%) |
| Dec 2015 | $3.33 M | $705.20 K(-32.5%) | $3.33 M(+26.9%) |
| Sept 2015 | - | $1.04 M(+27.9%) | $2.63 M(+66.1%) |
| June 2015 | - | $817.00 K(+7.0%) | $1.58 M(+107.0%) |
| Mar 2015 | - | $763.60 K | $763.60 K |
FAQ
- What is Entero Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Entero Therapeutics?
- What is Entero Therapeutics annual SG&A year-on-year change?
- What is Entero Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Entero Therapeutics?
- What is Entero Therapeutics quarterly SG&A year-on-year change?
- What is Entero Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Entero Therapeutics?
- What is Entero Therapeutics TTM SG&A year-on-year change?
What is Entero Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of ENTO is $10.74 M
What is the all time high annual SG&A for Entero Therapeutics?
Entero Therapeutics all-time high annual selling, general & administrative expenses is $18.38 M
What is Entero Therapeutics annual SG&A year-on-year change?
Over the past year, ENTO annual selling, general & administrative expenses has changed by -$1.25 M (-10.42%)
What is Entero Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of ENTO is $1.69 M
What is the all time high quarterly SG&A for Entero Therapeutics?
Entero Therapeutics all-time high quarterly selling, general & administrative expenses is $8.66 M
What is Entero Therapeutics quarterly SG&A year-on-year change?
Over the past year, ENTO quarterly selling, general & administrative expenses has changed by -$1.10 M (-39.50%)
What is Entero Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of ENTO is -$740.81 M
What is the all time high TTM SG&A for Entero Therapeutics?
Entero Therapeutics all-time high TTM selling, general & administrative expenses is $18.38 M
What is Entero Therapeutics TTM SG&A year-on-year change?
Over the past year, ENTO TTM selling, general & administrative expenses has changed by -$751.55 M (-6999.26%)